Vivesto AB (VIVE.ST)
SEK 0.23
(-1.71%)
SEK 0.23
(-1.71%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | -10.65 Million SEK | 40.57% |
| 2021 | -17.93 Million SEK | -108.31% |
| 2020 | 215.84 Million SEK | 0.0% |
| 2019 | 215.84 Million SEK | 3625.96% |
| 2018 | 5.79 Million SEK | -26.88% |
| 2017 | 7.92 Million SEK | 182.36% |
| 2016 | 2.8 Million SEK | -89.93% |
| 2015 | 27.87 Million SEK | 216.59% |
| 2014 | 8.8 Million SEK | -61.19% |
| 2013 | 22.68 Million SEK | -46.61% |
| 2012 | 42.49 Million SEK | -21.37% |
| 2011 | 54.04 Million SEK | -22.83% |
| 2010 | 70.03 Million SEK | -24.32% |
| 2009 | 92.54 Million SEK | 57.32% |
| 2008 | 58.82 Million SEK | 65.59% |
| 2007 | 35.52 Million SEK | 150.23% |
| 2006 | 14.19 Million SEK | 139.59% |
| 2005 | 5.92 Million SEK | 67.44% |
| 2004 | 3.53 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q1 | - SEK | 100.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2022 Q3 | 129 Thousand SEK | 113.12% |
| 2022 FY | -10.65 Million SEK | 40.57% |
| 2022 Q1 | -11 Thousand SEK | -101.51% |
| 2022 Q2 | -983 Thousand SEK | -8836.36% |
| 2022 Q4 | -9.79 Million SEK | -7689.92% |
| 2021 Q1 | -2000.00 SEK | 100.0% |
| 2021 Q4 | 729 Thousand SEK | 393.95% |
| 2021 Q2 | -18.4 Million SEK | -920350.0% |
| 2021 Q3 | -248 Thousand SEK | 98.65% |
| 2021 FY | -17.93 Million SEK | -108.31% |
| 2020 Q1 | 207.86 Million SEK | 46297.54% |
| 2020 Q2 | 1.55 Million SEK | -99.25% |
| 2020 Q3 | 16.52 Million SEK | 964.69% |
| 2020 Q4 | -202.78 Million SEK | -1327.2% |
| 2020 FY | 215.84 Million SEK | 0.0% |
| 2019 Q1 | -1.29 Million SEK | -163.27% |
| 2019 Q4 | 448 Thousand SEK | -91.48% |
| 2019 FY | 215.84 Million SEK | 3625.96% |
| 2019 Q3 | 5.25 Million SEK | 130.57% |
| 2019 Q2 | 2.28 Million SEK | 275.52% |
| 2018 Q2 | 1.37 Million SEK | 16.33% |
| 2018 FY | 5.79 Million SEK | -26.88% |
| 2018 Q4 | 2.05 Million SEK | -43.94% |
| 2018 Q1 | 1.18 Million SEK | -40.99% |
| 2018 Q3 | 3.66 Million SEK | 166.33% |
| 2017 Q2 | 1.88 Million SEK | 181.07% |
| 2017 Q4 | 2 Million SEK | -29.69% |
| 2017 FY | 7.92 Million SEK | 182.36% |
| 2017 Q3 | 2.84 Million SEK | 50.82% |
| 2017 Q1 | -2.33 Million SEK | -167.3% |
| 2016 FY | 2.8 Million SEK | -89.93% |
| 2016 Q1 | 4.6 Million SEK | -72.51% |
| 2016 Q4 | 3.46 Million SEK | 2305.1% |
| 2016 Q3 | -157 Thousand SEK | -108.59% |
| 2016 Q2 | 1.82 Million SEK | -60.32% |
| 2015 Q1 | 1.94 Million SEK | 105.06% |
| 2015 Q4 | 16.76 Million SEK | 664.25% |
| 2015 Q2 | 4.31 Million SEK | 121.91% |
| 2015 Q3 | 2.19 Million SEK | -49.17% |
| 2015 FY | 27.87 Million SEK | 216.59% |
| 2014 Q2 | 1.24 Million SEK | -70.93% |
| 2014 Q3 | 4.66 Million SEK | 274.56% |
| 2014 Q4 | 948 Thousand SEK | -79.69% |
| 2014 Q1 | 4.28 Million SEK | -35.64% |
| 2014 FY | 8.8 Million SEK | -61.19% |
| 2013 Q4 | 6.65 Million SEK | 10.95% |
| 2013 Q3 | 6 Million SEK | 4.55% |
| 2013 Q2 | 5.74 Million SEK | -39.97% |
| 2013 Q1 | 9.56 Million SEK | -0.46% |
| 2013 FY | 22.68 Million SEK | -46.61% |
| 2012 Q3 | -15.36 Million SEK | -92.82% |
| 2012 Q4 | 9.6 Million SEK | 162.55% |
| 2012 FY | 42.49 Million SEK | -21.37% |
| 2012 Q1 | 115.59 Million SEK | 698.72% |
| 2012 Q2 | -7.96 Million SEK | -106.89% |
| 2011 Q4 | -19.3 Million SEK | -1513.4% |
| 2011 FY | 54.04 Million SEK | -22.83% |
| 2011 Q1 | 13.64 Million SEK | -45.63% |
| 2011 Q2 | 17.32 Million SEK | 26.96% |
| 2011 Q3 | 1.36 Million SEK | -92.11% |
| 2010 Q2 | 17.39 Million SEK | -18.21% |
| 2010 Q3 | 13.89 Million SEK | -20.11% |
| 2010 Q4 | 25.09 Million SEK | 80.57% |
| 2010 FY | 70.03 Million SEK | -24.32% |
| 2010 Q1 | 21.27 Million SEK | 148.66% |
| 2009 Q4 | 8.55 Million SEK | -51.4% |
| 2009 Q2 | 45.11 Million SEK | 0.0% |
| 2009 Q3 | 17.6 Million SEK | -60.99% |
| 2009 FY | 92.54 Million SEK | 57.32% |
| 2008 FY | 58.82 Million SEK | 65.59% |
| 2007 FY | 35.52 Million SEK | 150.23% |
| 2006 FY | 14.19 Million SEK | 139.59% |
| 2005 FY | 5.92 Million SEK | 67.44% |
| 2004 FY | 3.53 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AcuCort AB | 6.59 Million SEK | 261.65% |
| AlzeCure Pharma AB (publ) | -476 Thousand SEK | -2138.655% |
| BioGaia AB (publ) | 950.19 Million SEK | 101.121% |
| Enzymatica AB (publ) | 31.86 Million SEK | 133.443% |
| Enorama Pharma AB (publ) | -3.9 Million SEK | -173.161% |
| Gabather AB (publ) | - SEK | Infinity% |
| Klaria Pharma Holding AB (publ.) | -9000.00 SEK | -118300.0% |
| Moberg Pharma AB (publ) | -2.09 Million SEK | -407.67% |
| Nanexa AB (publ) | 59.15 Million SEK | 118.013% |
| Newbury Pharmaceuticals AB (publ) | 16.03 Million SEK | 166.463% |
| ODI Pharma AB | -1.34 Million SEK | -694.255% |
| Orexo AB (publ) | 549.9 Million SEK | 101.938% |
| Probi AB (publ) | 220.21 Million SEK | 104.839% |
| Swedencare AB (publ) | 164.8 Million SEK | 106.466% |
| Swedish Orphan Biovitrum AB (publ) | 14.05 Billion SEK | 100.076% |
| Toleranzia AB | -919 Thousand SEK | -1059.521% |